JP2017515841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515841A5 JP2017515841A5 JP2016567413A JP2016567413A JP2017515841A5 JP 2017515841 A5 JP2017515841 A5 JP 2017515841A5 JP 2016567413 A JP2016567413 A JP 2016567413A JP 2016567413 A JP2016567413 A JP 2016567413A JP 2017515841 A5 JP2017515841 A5 JP 2017515841A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- taa
- antagonist
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072789A JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992771P | 2014-05-13 | 2014-05-13 | |
| US61/992,771 | 2014-05-13 | ||
| PCT/US2015/029885 WO2015175340A1 (en) | 2014-05-13 | 2015-05-08 | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072789A Division JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515841A JP2017515841A (ja) | 2017-06-15 |
| JP2017515841A5 true JP2017515841A5 (enExample) | 2018-06-07 |
Family
ID=53264790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567413A Pending JP2017515841A (ja) | 2014-05-13 | 2015-05-08 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| JP2020072789A Active JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072789A Active JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3142689B1 (enExample) |
| JP (2) | JP2017515841A (enExample) |
| AU (1) | AU2015259516B2 (enExample) |
| CA (1) | CA2946606C (enExample) |
| DK (1) | DK3142689T3 (enExample) |
| ES (1) | ES2851451T3 (enExample) |
| IL (1) | IL248511B (enExample) |
| WO (1) | WO2015175340A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| CN109071592B (zh) | 2016-01-08 | 2022-07-19 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
| US20190030157A1 (en) | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
| CN107281474A (zh) * | 2016-04-11 | 2017-10-24 | 中国科学院上海巴斯德研究所 | 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物 |
| CN116693685A (zh) | 2016-04-12 | 2023-09-05 | 法国施维雅药厂 | 抗tim-3抗体及组合物 |
| PT3463436T (pt) | 2016-06-02 | 2023-12-28 | Ultimovacs As | Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| AU2018247916B2 (en) * | 2017-04-05 | 2025-04-24 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
| CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| US20210046130A1 (en) * | 2018-01-24 | 2021-02-18 | Virogin Biotech Canada Ltd | Recombinant viral vaccines |
| CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| US20230233670A1 (en) * | 2020-06-10 | 2023-07-27 | Bavarian Nordic A/S | A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| CN1135181A (zh) | 1993-09-14 | 1996-11-06 | Cytel有限公司 | 使用泛dr结合肽改变免疫应答 |
| US6165460A (en) | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| EP0954593A1 (en) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| KR100731820B1 (ko) | 1998-10-05 | 2007-06-25 | 파멕사 에이/에스 | 치료적 백신화를 위한 새로운 방법 |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| WO2005046622A2 (en) * | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| BRPI0509139A (pt) * | 2004-03-24 | 2007-08-28 | Telos Fharmaceuticals Inc | composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2009097394A2 (en) * | 2008-01-29 | 2009-08-06 | The Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| WO2011041613A2 (en) | 2009-09-30 | 2011-04-07 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| JP5760796B2 (ja) | 2011-07-22 | 2015-08-12 | 富士通株式会社 | 冷却ユニット |
| EP2744830A4 (en) | 2012-06-21 | 2015-06-17 | Compugen Ltd | LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER |
| EP2908851A1 (en) * | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
-
2015
- 2015-05-08 ES ES15724454T patent/ES2851451T3/es active Active
- 2015-05-08 CA CA2946606A patent/CA2946606C/en active Active
- 2015-05-08 IL IL248511A patent/IL248511B/en unknown
- 2015-05-08 WO PCT/US2015/029885 patent/WO2015175340A1/en not_active Ceased
- 2015-05-08 JP JP2016567413A patent/JP2017515841A/ja active Pending
- 2015-05-08 DK DK15724454.2T patent/DK3142689T3/da active
- 2015-05-08 AU AU2015259516A patent/AU2015259516B2/en active Active
- 2015-05-08 EP EP15724454.2A patent/EP3142689B1/en active Active
-
2020
- 2020-04-15 JP JP2020072789A patent/JP7368305B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515837A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| DeMaria et al. | Cancer vaccines | |
| JP7368305B2 (ja) | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 | |
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| RU2016122035A (ru) | Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки | |
| Yang et al. | DNA vaccine for cancer immunotherapy | |
| Madan et al. | Clinical evaluation of TRICOM vector therapeutic cancer vaccines | |
| JP2022507744A5 (enExample) | ||
| JP2018522822A5 (enExample) | ||
| Milani et al. | Recent advances in the development of breast cancer vaccines | |
| EP2596801A1 (en) | Methods for treating cancer with mva | |
| EP3545965A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| JP2023503857A5 (enExample) | ||
| Nicolini et al. | The use of immunotherapy to treat metastatic breast cancer | |
| JP2021528367A (ja) | 免疫応答を誘導するための組成物 | |
| Haldar et al. | Worth a pound of cure? Emerging strategies and challenges in cancer immunoprevention | |
| Zhang et al. | Management of castrate resistant prostate cancer—recent advances and optimal sequence of treatments | |
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| JP6297641B2 (ja) | 愛玩動物の癌の補助治療としてのＨｅｒ２ＤＮＡワクチン | |
| JP2018531238A6 (ja) | 抗腫瘍性組成物 | |
| US20110104101A1 (en) | Immunotherapy for Unresectable Pancreatic Cancer | |
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination | |
| Plunkett et al. | Immunotherapy: the last 25 years |